CCO Treatment Updates
HIV Entry and Tropism: New Strategies for Effective Antiretroviral Therapy
Understanding HIV Entry and Targets for Therapy |
Module 1 of 4 |
|
|
|
Robert W. Doms, MD, PhD, discusses the mechanisms of HIV entry into host cells and how those mechanisms provide targets for antiretroviral therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the mechanisms associated with HIV entry into the host cell
- Identify steps in the viral entry process that represent targets for antiretroviral therapy
- Discuss the mechanisms by which resistance to HIV entry inhibitors may occur
|
Tracking Tropism: Epidemiology and Clinical Tools |
Module 2 of 4 |
|
|
|
Jürgen K. Rockstroh, MD, discusses the incidence of HIV coreceptor types across different patient populations and the assays available to determine a particular patient’s viral tropism.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the different types of host-cell coreceptors and their roles in HIV transmission and disease progression
- Discuss the difference in coreceptor expression between antiretroviral-naive and antiretroviral-experienced patient populations
- Discuss the use of the phenotypic tropism assay in managing HIV-infected patients
|
Recent Clinical Studies of HIV Entry Inhibitors |
Module 3 of 4 |
- Anton L. Pozniak, MD, FRCP
|
|
|
Anton L. Pozniak, MD, FRCP, discusses recent and ongoing clinical trials of both approved and investigational HIV entry inhibitors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the types of HIV entry inhibitors that have been approved or are currently in clinical trials
- Discuss the key findings of the MOTIVATE trials of maraviroc
- Discuss the appropriate use of enfuvirtide in treatment-experienced HIV-infected patients
|
Entry Inhibitors in Clinical Practice: Strategies to Achieve Treatment Goals |
Module 4 of 4 |
|
|
|
Eric S. Daar, MD, discusses the importance of understanding the impact of introducing new classes of antiretrovirals into a treatment regimen and strategies for doing so successfully.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the key steps that need to be taken in managing antiretroviral-experienced patients
- Discuss the impact on clinical outcomes of introducing novel classes of antiretroviral agents into a treatment regimen
- Identify the factors that should be considered in deciding whether a patient is an appropriate candidate for treatment with HIV entry inhibitors
|
CCO Slidesets
Understanding HIV Entry and Targets for Therapy
 |
|
This slideset reviews mechanisms of HIV entry and targets for therapy.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.96 MB
|
Tracking Tropism: Epidemiology and Clinical Tools
 |
|
This slideset reviews the definition of viral tropism, the prognostic value of tropism, coreceptor use in different patient populations, and tropism assays.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.03 MB
|
Recent Clinical Studies of HIV Entry Inhibitors
 |
|
This slideset reviews recent clinical trial data involving the use of HIV entry inhibitors.
Format: Microsoft PowerPoint (.ppt) |
File size: 926 KB
|
Entry Inhibitors in Clinical Practice: Strategies to Achieve Treatment Goals
 |
|
This slideset discusses the use of entry inhibitors in clinical settings and outlines strategies to achieve treatment goals.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.49 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|